Annals of Hematology
Latest Publications


TOTAL DOCUMENTS

6940
(FIVE YEARS 1145)

H-INDEX

74
(FIVE YEARS 11)

Published By Springer-Verlag

1432-0584, 0939-5555

Author(s):  
Akio Onishi ◽  
Shigeo Fuji ◽  
Shigehisa Kitano ◽  
Akiko Miyagi Maeshima ◽  
Kinuko Tajima ◽  
...  

Author(s):  
F. Tiso ◽  
T. N. Koorenhof-Scheele ◽  
E. Huys ◽  
J. H. A. Martens ◽  
A. O. de Graaf ◽  
...  

AbstractAcute myeloid leukemia (AML) is a highly heterogeneous disease showing dynamic clonal evolution patterns over time. Various subclones may be present simultaneously and subclones may show a different expansion pattern and respond differently to applied therapies. It is already clear that immunophenotyping and genetic analyses may yield overlapping, but also complementary information. Detailed information on the genetic make-up of immunophenotypically defined subclones is however scarce. We performed error-corrected sequencing for 27 myeloid leukemia driver genes in 86, FACS-sorted immunophenotypically characterized normal and aberrant subfractions in 10 AML patients. We identified three main scenarios. In the first group of patients, the two techniques were equally well characterizing the malignancy. In the second group, most of the isolated populations did not express aberrant immunophenotypes but still harbored several genetic aberrancies, indicating that the information obtained only by immunophenotyping would be incomplete. Vice versa, one patient was identified in which genetic mutations were found only in a small fraction of the immunophenotypically defined malignant populations, indicating that the genetic analysis gave an incomplete picture of the disease. We conclude that currently, characterization of leukemic cells in AML by molecular and immunophenotypic techniques is complementary, and infer that both techniques should be used in parallel in order to obtain the most complete view on the disease.


Author(s):  
Roswitha Lüftinger ◽  
Natalia Zubarovskaya ◽  
Jacques-Emmanuel Galimard ◽  
Annamaria Cseh ◽  
Elisabeth Salzer ◽  
...  

Author(s):  
Larissa Henze ◽  
Christoph Buhl ◽  
Michael Sandherr ◽  
Oliver A. Cornely ◽  
Werner J. Heinz ◽  
...  

Abstract Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus.


Author(s):  
Zhao Xu ◽  
Yifeng Sun ◽  
Jifeng Jiang ◽  
Peng Liu
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document